Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Receivables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Change in Receivables for 4 consecutive years, with $92972.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 149.46% to $92972.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$597242.0 through Dec 2025, down 282.35% year-over-year, with the annual reading at -$597242.0 for FY2025, 282.35% down from the prior year.
  • Change in Receivables for Q4 2025 was $92972.0 at bioAffinity Technologies, up from $27121.0 in the prior quarter.
  • The five-year high for Change in Receivables was $472017.0 in Q2 2024, with the low at -$541875.0 in Q2 2025.
  • Average Change in Receivables over 4 years is -$35757.4, with a median of $757.5 recorded in 2022.
  • The sharpest move saw Change in Receivables crashed 42949.02% in 2023, then surged 57880.48% in 2024.
  • Over 4 years, Change in Receivables stood at $559.0 in 2022, then plummeted by 42949.02% to -$239526.0 in 2023, then grew by 21.53% to -$187964.0 in 2024, then skyrocketed by 149.46% to $92972.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $92972.0, $27121.0, and -$541875.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.